NCT01221974CompletedPhase 1
Use of Essure® Micro-inserts in Women With Hydrosalpinx Prior to In Vitro Fertilization: A Prospective, Multicenter, International Feasibility Study
Reproductive Science Center2 sites in 1 countryStarted: July 1, 2008Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Locations
- 2
Study Overview
Brief Summary
The purpose of this study is to gather safety data related to the use of Essure® micro-inserts in women with hydrosalpinx prior to in vitro fertilization and during pregnancy and to collect data with regard to implantation rates, clinical pregnancy rates, and pregnancy outcomes.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
Eligibility Criteria
- Ages
- 21 Years to 38 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Women age 21-38 (unless women in ovum donor cycle then age will be included up to 43) who:
- •Are willing to participate in this clinical study Are able to comprehend and give informed consent for participation in this study Have read, understood and signed an informed consent form Have been unable to achieve pregnancy after trying for 1 year or greater and who have unilateral or bilateral hydrosalpinges as evidenced by laparoscopy or ultrasound or HSG Have a Day #3 serum FSH<10, and Day #3 Estradiol<80 Recipient women undergoing a ovum donor cycle the donor must have a Day 3 serum FSH < 10 and Day 3 Estradiol < 80 Have an antral follicle count 10 or greater for both ovaries combined, if women using ovum donor (follicle count) will be based on eligible donor Have a desire to receive treatment for their HS Are willing to undergo a hysterosalpingogram (HSG) 3 months after Essure placement to confirm proximal tubal occlusion
Exclusion Criteria
- •Active or recent upper or lower pelvic infection Known hypersensitivity to nickel as confirmed by skin test Known allergy to contrast media Pregnancy or suspected pregnancy Delivery or termination of pregnancy less than six weeks prior to Essure micro-insert placements BMI > 35 Abnormal pap smear (CIN2 or greater abnormality) within the past year Pelvic malignancy Severely retroverted uterus Evidence of intrauterine abnormalities such as submucous fibroids, polyps, intrauterine adhesions or presence of a uterine septum Abnormal Clomid Challenge Test or abnormal lab values on Day #3 serum FSH and Estradiol Antral follicle count less than 10 (both ovaries combined) Poor general or gynecologic health Inability or refusal to provide informed consent
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Improvement of Symptoms After Removal of the Essure® Contraceptive ImplantImplant ComplicationContraceptive Device ComplicationsNCT06355713Hospices Civils de Lyon444
Completed
Not Applicable
Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in WomenContraceptionNCT01948882Bayer660
Terminated
Phase 2
Hysteroscopic Lymphatic Mapping for Endometrial CancerEndometrial CancerNCT00671606M.D. Anderson Cancer Center5
Completed
Phase 3
Recombinant Hyaluronidase in Out-of-Hospital Setting: The EASI Access TrialMass Casualty IncidentDehydrationNCT00386386Massachusetts General Hospital20
Completed
Not Applicable
A Pilot Clinical Study of the Efficacy and Safety of a Disposable Intravaginal Device for Stress Urinary IncontinenceStress Urinary IncontinenceNCT01762345Procter and Gamble148